Moreover, we have demonstrated that in a variety of tumors, the expression of IMPDH1 attenuated the efficacy of immunotherapy and reduced the survival of tumor patients through using different databases, which was more convincing that as IMPDH1, as an undesirable immune molecule, its inhibitors might be used as sensitizers in cancer immunotherapy to benefit patients. This evidence concerns the gene IMPDH1 and neoplasm.